See more : Myers Industries, Inc. (MYE) Income Statement Analysis – Financial Results
Complete financial analysis of Recursion Pharmaceuticals, Inc. (RXRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Recursion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Paramount Gold Nevada Corp. (PZG) Income Statement Analysis – Financial Results
- TCI Co., Ltd. (8436.TWO) Income Statement Analysis – Financial Results
- Ampol Limited (CTXAY) Income Statement Analysis – Financial Results
- Tootsie Roll Industries, Inc. (TR) Income Statement Analysis – Financial Results
- Kelso Technologies Inc. (KLS.TO) Income Statement Analysis – Financial Results
Recursion Pharmaceuticals, Inc. (RXRX)
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 44.58M | 39.68M | 10.00M | 3.41M | 1.71M |
| Cost of Revenue | 42.59M | 48.28M | 9.10M | 63.32M | 45.81M |
| Gross Profit | 1.99M | -8.59M | 896.00K | -59.91M | -44.10M |
| Gross Profit Ratio | 4.46% | -21.66% | 8.96% | -1,755.23% | -2,577.32% |
| Research & Development | 241.23M | 155.70M | 135.27M | 63.32M | 45.81M |
| General & Administrative | 110.82M | 81.60M | 57.68M | 25.26M | 18.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 110.82M | 81.60M | 57.68M | 25.26M | 18.95M |
| Other Expenses | 0.00 | -162.00K | -178.00K | -549.00K | -608.00K |
| Operating Expenses | 352.05M | 237.13M | 192.78M | 88.03M | 64.15M |
| Cost & Expenses | 394.64M | 285.41M | 192.78M | 88.03M | 64.15M |
| Interest Income | 19.12M | 6.25M | 73.00K | 336.00K | 1.74M |
| Interest Expense | 97.00K | 55.00K | 2.95M | 1.36M | 635.00K |
| Depreciation & Amortization | 24.40M | 19.49M | 9.10M | 4.44M | 3.54M |
| EBITDA | -299.57M | -227.67M | -174.42M | -81.70M | -58.34M |
| EBITDA Ratio | -672.05% | -619.26% | -1,827.75% | -2,353.38% | -3,401.52% |
| Operating Income | -350.06M | -245.73M | -182.78M | -84.62M | -62.44M |
| Operating Income Ratio | -785.33% | -619.26% | -1,827.75% | -2,479.20% | -3,649.39% |
| Total Other Income/Expenses | 17.93M | 6.25M | -3.70M | -2.39M | 562.00K |
| Income Before Tax | -332.13M | -239.48M | -186.48M | -87.01M | -61.88M |
| Income Before Tax Ratio | -745.10% | -603.50% | -1,864.79% | -2,549.25% | -3,616.54% |
| Income Tax Expense | -4.06M | -55.00K | -8.41M | 876.00K | 646.00K |
| Net Income | -328.07M | -239.42M | -178.07M | -87.88M | -62.53M |
| Net Income Ratio | -735.99% | -603.36% | -1,780.74% | -2,574.92% | -3,654.30% |
| EPS | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| EPS Diluted | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Weighted Avg Shares Out | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
| Weighted Avg Shares Out (Dil) | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
Is Recursion Pharmaceuticals Stock a Buy?
ANGLE signs pilot study agreement with AI-powered Recursion Pharmaceuticals
Cathie Wood's Stock Shuffle: 1 Stock She's Loving, 1 She's Leaving
Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
Recursion's blood vessel disorder drug meets main goal in mid-stage study
Source: https://incomestatements.info
Category: Stock Reports